Kazia Therapeutics Closes Public Offering, Raising Up To $120 Million
Oncology-focused biotechnology firm Kazia Therapeutics announced the closing of its public offering, raising up to $120 million. The company will host a corporate update call on September 1st.
Kazia Therapeutics Limited, a biotechnology company developing therapies for cancer, announced on Tuesday the closing of its public offering. The offering, which was oversubscribed, raised up to $120 million.
The funds are earmarked to advance the company's clinical programs, including the development of its lead candidate, paxalisib. Paxalisib is an investigational drug being studied for the treatment of patients with previously untreated glioblastoma. Kazia is also exploring paxalisib in other cancer types.
The company plans to host a corporate update call on Tuesday, September 1st, at 8:00 AM ET. The call will provide details on the company's recent progress and future outlook.
The successful financing comes amid growing interest in novel cancer therapies and Kazia's specific approach to reprogramming cancer biology.